The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
Matthew Raymond Smith
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Christopher Sweeney
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Dana E. Rathkopf
No relevant relationships to disclose
Howard I. Scher
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis
Christopher Logothetis
Research Funding - Exelixis
Daniel J. George
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Celestia S. Higano
Research Funding - Exelixis
Evan Y. Yu
No relevant relationships to disclose
Andrea Lynne Harzstark
No relevant relationships to disclose
Eric Jay Small
Research Funding - Exelixis
A. Oliver Sartor
No relevant relationships to disclose
Michael S. Gordon
Research Funding - Exelixis
Nicholas J. Vogelzang
Research Funding - Exelixis
David C. Smith
Research Funding - Exelixis
Maha Hussain
Consultant or Advisory Role - Exelixis (U)
Johann Sebastian De Bono
No relevant relationships to disclose
Naomi B. Haas
No relevant relationships to disclose
Christian Scheffold
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yihua Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Paul G. Corn
No relevant relationships to disclose